ArticleFrontiers in pharmacology2025
Therapeutic potential of a rhein-loaded self-nano-emulsifying drug delivery system in ameliorating LPS-induced depression: mechanistic insights and behavioral outcomes.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Research Progress of Functionalized Drug Delivery Nanosystems in Regulating Depression.Pharmaceuticals (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Depression is a multifaceted disorder caused by neuroinflammation, which is mainly demarcated by a significant increase in proinflammatory cytokines, including interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α). Conventional treatments for depression typically focus on neurotransmitter theories and may lead to several undesirable side effects. Therefore, it is essential to identify innovative active compounds of herbal origin that can target proinflammatory cytokines to reduce neuroinflammation while minimizing side effects. Rhein has demonstrated considerable therapeutic efficacy in various neurological conditions; however, its mechanistic insights regarding antidepressant effects remain unclear. An
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.